BRPI0017596B8 - método para radiomarcação de um anticorpo conjugado a um quelante com 111in para administração a um paciente - Google Patents

método para radiomarcação de um anticorpo conjugado a um quelante com 111in para administração a um paciente

Info

Publication number
BRPI0017596B8
BRPI0017596B8 BRPI0017596A BRPI0017596A BRPI0017596B8 BR PI0017596 B8 BRPI0017596 B8 BR PI0017596B8 BR PI0017596 A BRPI0017596 A BR PI0017596A BR PI0017596 A BRPI0017596 A BR PI0017596A BR PI0017596 B8 BRPI0017596 B8 BR PI0017596B8
Authority
BR
Brazil
Prior art keywords
radiolabeling
antibody
chelator
antibody conjugated
administration
Prior art date
Application number
BRPI0017596A
Other languages
English (en)
Portuguese (pt)
Inventor
Chinn Paul
Morena Ronald
Labarre Michael
E Loenard John
Original Assignee
Idec Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idec Pharma Corp filed Critical Idec Pharma Corp
Publication of BRPI0017596A2 publication Critical patent/BRPI0017596A2/pt
Publication of BRPI0017596B1 publication Critical patent/BRPI0017596B1/pt
Publication of BRPI0017596B8 publication Critical patent/BRPI0017596B8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Packages (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0017596A 1999-03-01 2000-02-29 método para radiomarcação de um anticorpo conjugado a um quelante com 111in para administração a um paciente BRPI0017596B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/259,337 US20020102208A1 (en) 1999-03-01 1999-03-01 Radiolabeling kit and binding assay
BRPI0008719-0 BRPI0008719B8 (pt) 1999-03-01 2000-02-29 Método para radiomarcação de um anticorpo conjugado a um quelante com 90y e ensaio de ligação para determinação da ligação percentual de um anticorpo radiomarcado à sua célula alvo
PCT/US2000/005061 WO2000052473A2 (en) 1999-03-01 2000-02-29 Radiolabeling kit and binding assay

Publications (3)

Publication Number Publication Date
BRPI0017596A2 BRPI0017596A2 (pt) 2011-09-27
BRPI0017596B1 BRPI0017596B1 (pt) 2015-09-01
BRPI0017596B8 true BRPI0017596B8 (pt) 2023-04-25

Family

ID=22984524

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0017596A BRPI0017596B8 (pt) 1999-03-01 2000-02-29 método para radiomarcação de um anticorpo conjugado a um quelante com 111in para administração a um paciente
BRPI0008719-0 BRPI0008719B8 (pt) 1999-03-01 2000-02-29 Método para radiomarcação de um anticorpo conjugado a um quelante com 90y e ensaio de ligação para determinação da ligação percentual de um anticorpo radiomarcado à sua célula alvo

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0008719-0 BRPI0008719B8 (pt) 1999-03-01 2000-02-29 Método para radiomarcação de um anticorpo conjugado a um quelante com 90y e ensaio de ligação para determinação da ligação percentual de um anticorpo radiomarcado à sua célula alvo

Country Status (35)

Country Link
US (2) US20020102208A1 (https=)
EP (2) EP2112512B1 (https=)
JP (1) JP4704570B2 (https=)
KR (1) KR100729247B1 (https=)
CN (1) CN1235639C (https=)
AT (1) ATE433108T1 (https=)
AU (1) AU776747B2 (https=)
BG (1) BG65690B1 (https=)
BR (2) BRPI0017596B8 (https=)
CA (2) CA2362119C (https=)
CY (2) CY1109335T1 (https=)
CZ (2) CZ303262B6 (https=)
DE (1) DE60042326D1 (https=)
DK (2) DK2112512T3 (https=)
EE (1) EE05650B1 (https=)
ES (2) ES2328100T3 (https=)
HK (1) HK1045730B (https=)
HR (1) HRP20010714B1 (https=)
HU (2) HU229627B1 (https=)
IL (1) IL145109A0 (https=)
ME (1) ME00782B (https=)
MX (1) MXPA01008837A (https=)
MY (1) MY138674A (https=)
NO (2) NO329142B1 (https=)
NZ (2) NZ513788A (https=)
PL (1) PL205780B1 (https=)
PT (2) PT1192463E (https=)
RS (1) RS51778B (https=)
RU (1) RU2251110C2 (https=)
SI (2) SI2112512T1 (https=)
SK (2) SK287745B6 (https=)
TW (1) TWI294969B (https=)
UA (1) UA78484C2 (https=)
WO (1) WO2000052473A2 (https=)
ZA (1) ZA200106943B (https=)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US20020102208A1 (en) * 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US6207858B1 (en) * 1999-03-03 2001-03-27 Idec Pharmaceuticals Corporation Regioselective synthesis of DTPA derivatives
EP1918305A1 (en) 1999-08-11 2008-05-07 Biogen Idec Inc. New clinical parameters for determining hematologic toxicity prior to radioimmunotherapy
JP4202127B2 (ja) 2000-10-02 2008-12-24 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アンタゴニスト抗ｃｄ４０抗体を用いるｂ細胞悪性腫瘍の治療方法
US20030003097A1 (en) * 2001-04-02 2003-01-02 Idec Pharmaceutical Corporation Recombinant antibodies coexpressed with GnTIII
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
EP2277542B1 (en) 2001-06-01 2014-04-16 Cornell Research Foundation Inc. Modified antibodies to prostrate-specific membrane antigen and uses thereof
IL159422A0 (en) 2001-09-20 2004-06-01 Cornell Res Foundation Inc Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen
ATE408712T1 (de) 2003-01-10 2008-10-15 Millennium Pharm Inc Verfahren zur bestimmung des wiederauftretens von prostata krebs
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
NZ543495A (en) * 2003-06-25 2009-04-30 Peregrine Pharmaceuticals Inc Method and apparatus for continuous large-scale radiolabeling of proteins
ATE474598T1 (de) 2003-11-04 2010-08-15 Novartis Vaccines & Diagnostic Verwendung von antagonisten-anti-cd40-antikörpern zur behandlung von chronisch lymphozytischer leukämie
CA2544951A1 (en) 2003-11-04 2005-05-19 Chiron Corporation Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
PT1694360E (pt) 2003-11-04 2010-12-13 Novartis Vaccines & Diagnostic Utilização de anticorpos monoclonais antagonistas anti-cd40 para o tratamento de doenças auto-imunes e inflamatórias e da rejeição ao transplante de orgãos
EP1680141B8 (en) 2003-11-04 2011-01-12 Novartis Vaccines and Diagnostics, Inc. Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
EP1844815B1 (en) 2003-11-04 2011-09-14 Novartis Vaccines and Diagnostics, Inc. Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers
WO2006125117A2 (en) 2005-05-18 2006-11-23 Novartis Ag Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
SI1904104T1 (sl) 2005-07-08 2013-12-31 Biogen Idec Ma Inc. Protitelesa SP35 in njihova uporaba
JP5123183B2 (ja) * 2005-08-25 2013-01-16 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 標的療法のための画像ベースの計画方法及び装置
DK2963011T3 (en) 2005-11-23 2018-08-06 Ventana Med Syst Inc MOLECULAR CONJUGATE
MX2008013508A (es) 2006-04-21 2008-10-31 Novartis Ag Composiciones farmaceuticas de anticuerpos antagonistas anti-cd40.
EP2037967B1 (en) 2006-06-16 2016-12-07 The Trustees Of The University Of Pennsylvania Prostaglandin d2 receptor antagonists for treating androgenetic alopecia
US9382327B2 (en) * 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
RU2448973C2 (ru) * 2006-11-10 2012-04-27 Альфаптозе ГмбХ Применение соединений три-замещенного глицерина для лечения радиационных поражений
CZ300074B6 (cs) * 2006-12-20 2009-01-21 Azacycles S. R. O. Inteligentní trífunkcní makrokonjugáty a farmaceutický nebo diagnostický prostredek s jejich obsahem
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
CN101636168B (zh) 2007-01-09 2013-05-29 比奥根艾迪克Ma公司 Sp35抗体及其用途
KR101247418B1 (ko) * 2007-12-21 2013-03-25 에프. 호프만-라 로슈 아게 항체 제형
DK2982695T3 (da) 2008-07-09 2019-05-13 Biogen Ma Inc Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
PE20141435A1 (es) 2008-07-16 2014-10-22 Inst Research In Biomedicine Anticuerpos neutralizantes de citomegalovirus humano
EP2303923B1 (en) 2008-07-16 2015-06-24 Institute for Research in Biomedicine Human cytomegalovirus neutralising antibodies and use thereof
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
WO2010010467A2 (en) 2008-07-25 2010-01-28 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
MX2011003588A (es) 2008-10-13 2011-10-14 Inst Research In Biomedicine Anticuerpos neutralizadores del virus del dengue y uso de los mismos.
JP2012514458A (ja) 2008-12-31 2012-06-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗リンホトキシン抗体
WO2011092593A2 (en) 2010-01-20 2011-08-04 Institute For Research In Biomedicine Hiv-1 neutralizing antibodies and uses thereof
ME02464B (me) 2010-03-12 2017-02-20 Genzyme Corp Kombinovana terapija za lečenje raka dojke
SG10201505217WA (en) 2010-07-09 2015-08-28 Biogen Hemophilia Inc Chimeric clotting factors
PL2601214T3 (pl) 2010-08-06 2018-05-30 Genzyme Corporation Kompozycje antagonistyczne wobec VEGF oraz ich zastosowania
AU2011288946A1 (en) * 2010-08-13 2013-03-21 Rdm Empreendimentos E Participacoes S.A. Method and composition for reducing the color of sugar
AU2012229336B2 (en) 2011-03-11 2017-02-02 Genzyme Corporation Pegylated Apelin and uses thereof
HRP20190714T1 (hr) 2011-07-18 2019-06-14 Institute For Research In Biomedicine Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
US9764038B2 (en) 2011-12-23 2017-09-19 Innate Pharma Enzymatic conjugation of antibodies
NZ630920A (en) 2012-03-20 2017-01-27 Humabs Biomed Sa Antibodies that neutralize rsv, mpv and pvm and uses thereof
RS57413B1 (sr) 2012-03-28 2018-09-28 Sanofi Sa Antitela za ligande bradikinin b1 receptora
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
RU2522203C2 (ru) * 2012-06-26 2014-07-10 Василий Александрович Ишутин Способ контроля стерилизации материалов и изделий
WO2014009426A2 (en) * 2012-07-13 2014-01-16 Innate Pharma Screening of conjugated antibodies
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
US10036010B2 (en) 2012-11-09 2018-07-31 Innate Pharma Recognition tags for TGase-mediated conjugation
CN110256560A (zh) 2013-03-11 2019-09-20 建新公司 通过糖工程的位点特异性抗体-药物偶联
WO2014165216A1 (en) 2013-03-12 2014-10-09 The Trustees Of The University Of Pennsylvania Diagnosing and treating cancer
EP2968582B1 (en) 2013-03-15 2020-07-01 Innate Pharma Solid phase tgase-mediated conjugation of antibodies
EP3010547B1 (en) 2013-06-20 2021-04-21 Innate Pharma Enzymatic conjugation of polypeptides
JP6744212B2 (ja) 2013-06-21 2020-08-19 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． ポリペプチドの酵素的結合
RU2558929C2 (ru) * 2013-08-08 2015-08-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" (НИИ Кардиологии) СПОСОБ ОПРЕДЕЛЕНИЯ СВЯЗЫВАНИЯ РАДИОФАРМПРЕПАРАТА НА ОСНОВЕ ЦИПРОФЛОКСАЦИНА, МЕЧЕННОГО 99mTc C БАКТЕРИЯМИ
TN2016000048A1 (en) 2013-08-13 2017-07-05 Sanofi Sa Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof
US11052177B2 (en) 2013-09-06 2021-07-06 The Trustees Of The University Of Pennsylvania Antimicrobial polymer layers
EP3733244A1 (en) 2013-10-02 2020-11-04 Medlmmune, LLC Neutralizing anti-influenza a antibodies and uses thereof
NZ723336A (en) 2014-02-27 2017-04-28 Univ Texas Methods and compositions for isolating exosomes
PL3129067T3 (pl) 2014-03-19 2023-05-08 Genzyme Corporation Specyficzne dla miejsca glikomodyfikowanie ugrupowań celujących
MA39708A (fr) 2014-03-27 2021-03-31 Bird Rock Bio Inc Anticorps qui se lient au récepteur cannabinoïde 1 (cb1) humain
CN119161468A (zh) 2014-07-15 2024-12-20 免疫医疗有限责任公司 中和抗乙型流感抗体及其用途
WO2016014613A1 (en) 2014-07-22 2016-01-28 The Trustees Of The University Of Pennsylvania Compositions and methods for cancer immunotherapy
WO2016055950A1 (en) 2014-10-08 2016-04-14 Novartis Ag Combination of human cytomegalovirus neutralizing antibodies
PT3204425T (pt) 2014-10-09 2020-12-18 Genzyme Corp Conjugados anticorpo fármaco glicomanipulados
WO2016075546A2 (en) 2014-11-14 2016-05-19 Antonio Lanzavecchia Antibodies that neutralize ebola virus and uses thereof
BR122020023406B1 (pt) 2014-11-18 2023-10-31 Institut Pasteur Anticorpos que neutralizam de modo potente vírus da raiva e outros lissavírus, moléculas de ácido nucleico, vetor, célula isolada, composição farmacêutica, usos dos mesmos, e kit de partes
CN113480640B (zh) 2015-06-01 2024-07-30 免疫医疗有限责任公司 中和抗流感结合分子及其用途
ES2947824T3 (es) 2015-07-30 2023-08-21 Univ Pennsylvania Alelos polimórficos de un solo nucleótido del gen DP-2 humano para la detección de la susceptibilidad a la inhibición del crecimiento del cabello por antagonistas de PGD2
US10278438B2 (en) 2015-08-31 2019-05-07 Grabbies Media, Llc Consumer usable device with redeemable member
US10633445B2 (en) 2015-09-15 2020-04-28 Board Of Regents The University Of Texas System T-cell receptor (TCR)-binding antibodies and uses thereof
BR112018006633A2 (en) 2015-09-30 2018-10-23 Bird Rock Bio, Inc. antibodies that bind to human cannabinoid receptor 1 (cb1)
WO2017059878A1 (en) 2015-10-07 2017-04-13 Humabs Biomed Sa Antibodies that potently neutralize hepatitis b virus and uses thereof
WO2017123685A1 (en) 2016-01-13 2017-07-20 Medimmune, Llc Method of treating influenza a
WO2018010789A1 (en) 2016-07-13 2018-01-18 Humabs Biomed Sa Novel antibodies specifically binding to zika virus epitopes and uses thereof
UA129243C2 (uk) 2017-04-19 2025-02-26 Інстітьют Фо Рісьорч Ін Біомедцін Антитіло, що зв'язується зі спорозоїтами p. falciparum
WO2018204895A1 (en) 2017-05-05 2018-11-08 Vaccinex, Inc. Human anti-semaphorin 4d antibody
BR112020001074A2 (pt) 2017-07-19 2020-07-14 Hoffman Technologies, Inc. composição
WO2019042555A1 (en) 2017-08-31 2019-03-07 Humabs Biomed Sa MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
CN109550061A (zh) * 2017-09-26 2019-04-02 南京江原安迪科正电子研究发展有限公司 一种用于放射性核素标记抗体的试剂盒及应用
RU2700584C1 (ru) * 2018-12-13 2019-09-18 Общество С Ограниченной Ответственностью "Апто-Фарм" Способ оценки сродства олигонуклеотида
MX2021006756A (es) 2018-12-19 2021-09-28 Humabs Biomed Sa Anticuerpos que neutralizan el virus de la hepatitis b y usos de los mismos.
MA55529A (fr) 2019-04-03 2022-02-09 Genzyme Corp Polypeptides de liaison anti-alpha bêta tcr à fragmentation réduite
KR20220063188A (ko) 2019-08-29 2022-05-17 비르 바이오테크놀로지, 인코포레이티드 B형 간염 바이러스 감염을 치료하기 위한 항체 조성물 및 방법
EP4110404A1 (en) 2020-02-28 2023-01-04 Genzyme Corporation Modified binding polypeptides for optimized drug conjugation
JP7748728B2 (ja) 2020-06-11 2025-10-03 インペリアル・カレッジ・イノベーションズ・リミテッド 末梢神経再生を促進するためのｃｘｃｌ１３結合分子の使用
JP2024504167A (ja) 2021-01-26 2024-01-30 ヴィア・バイオテクノロジー・インコーポレイテッド Ｂ型肝炎ウイルス感染を処置するための抗体組成物および方法
TW202430561A (zh) 2022-09-30 2024-08-01 法商賽諾菲公司 抗cd28抗體
KR20250094703A (ko) 2022-10-25 2025-06-25 아블린쓰 엔.브이. 향상된 효과기 기능을 갖는 당조작된 Fc 변이체 폴리펩타이드
US12195546B2 (en) 2022-12-19 2025-01-14 Sanofi CD28/OX40 bispecific antibodies
WO2025177185A1 (en) * 2024-02-20 2025-08-28 Janssen Biotech, Inc. Materials and methods for biologic affinity analysis
WO2025257408A1 (en) 2024-06-14 2025-12-18 Sanofi Treatment of solid organ transplant subjects with cd28/ox40 bispecific antibodies
WO2026024319A1 (en) 2024-07-23 2026-01-29 Bird Rock Bio Sub, Inc. Treatment of obesity and obstructive sleep apnea

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994966A (en) * 1972-09-28 1976-11-30 The Board Of Trustees Of The Leland Stanford Junior University Chelating agents
US4043998A (en) * 1974-10-09 1977-08-23 The Board Of Trustees Of The Leland Stanford Junior University 1-(P-benzenediazonium)-ethylenediamine tetraacetic acid
US4315851A (en) * 1978-12-29 1982-02-16 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
US4348376A (en) * 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4460559A (en) * 1980-03-03 1984-07-17 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4361544A (en) * 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4444744A (en) * 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4460561A (en) * 1980-03-03 1984-07-17 Goldenberg M David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4622420A (en) * 1980-03-18 1986-11-11 The Regents Of The University Of California Chelating agents and method
US4454106A (en) * 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
JPS5982222U (ja) * 1982-11-26 1984-06-02 松井　三郎 眼鏡
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4707352A (en) * 1984-01-30 1987-11-17 Enzo Biochem, Inc. Method of radioactively labeling diagnostic and therapeutic agents containing a chelating group
US4636380A (en) 1984-04-23 1987-01-13 Wong Dennis W Novel physiologic chemical method of labeling protein substances with the radionuclides of indium
US4634586A (en) * 1984-05-21 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Reagent and method for radioimaging leukocytes
US4722892A (en) * 1984-08-31 1988-02-02 Meares Claude F Monoclonal antibodies against metal chelates
US4824986A (en) * 1985-04-26 1989-04-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Metal chelate protein conjugate
US5101827A (en) * 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4735210A (en) * 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4926869A (en) * 1986-01-16 1990-05-22 The General Hospital Corporation Method for the diagnosis and treatment of inflammation
CA1266344A (en) * 1986-02-14 1990-02-27 Miki Kurami High molecular compounds having amino groups, and their utilization
US5099069A (en) 1986-09-05 1992-03-24 Gansow Otto A Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5246692A (en) * 1986-09-05 1993-09-21 The United States Of America As Represented By The Secretary Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US4831175A (en) * 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
EP0484989B1 (en) * 1986-09-05 1996-04-24 GANSOW, Otto A. Polysubstituted diethylenetriamine chelates for forming a metal-chelate-protein conjugate
US5034223A (en) * 1986-10-09 1991-07-23 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US4921690A (en) * 1986-12-29 1990-05-01 City Of Hope Method of enhancing the biodistribution of antibody for localization in lesions
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU619218B2 (en) 1987-11-06 1992-01-23 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
US5130118A (en) 1987-11-06 1992-07-14 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
US5217704A (en) 1987-11-06 1993-06-08 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
US4978745A (en) 1987-11-23 1990-12-18 Centocor, Inc. Immunoreactive heterochain antibodies
US4861579A (en) * 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
AU630362B2 (en) * 1988-05-25 1992-10-29 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Macrocyclic chelates & methods of use thereof
US4923985A (en) * 1988-05-25 1990-05-08 The United States Of America As Represented By The Department Of Health & Human Services Process for synthesizing macrocyclic chelates
US5059518A (en) * 1988-10-20 1991-10-22 Coulter Corporation Stabilized lyophilized mammalian cells and method of making same
CA2010511A1 (en) 1989-03-01 1990-09-01 Roberto L. Ceriani Method of enhancing cancer therapy by administration of unsaturated fatty acids
US5376356A (en) * 1989-03-14 1994-12-27 Neorx Corporation Imaging tissue sites of inflammation
US5162115A (en) * 1989-05-09 1992-11-10 Pietronigro Dennis D Antineoplastic solution and method for treating neoplasms
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
US5124471A (en) * 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
US5219556A (en) * 1990-07-09 1993-06-15 Mallinckrodt Medical, Inc. Stabilized therapeutic radiopharmaceutical complexes
US5009069A (en) * 1990-08-24 1991-04-23 Molini Alberto E Method of recovering energy from ocean water
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
JPH06501705A (ja) 1990-11-05 1994-02-24 ブリストル−マイアーズ　スクイブ　カンパニー 抗−腫瘍抗体及び生物学的活性剤の組合せによる相乗治療
US5208008A (en) * 1990-11-14 1993-05-04 University Of Pittsburgh Regioselective chemical modification of monoclonal antibodies
IL100626A0 (en) * 1991-01-11 1992-09-06 Cryopharm Corp A method of forming dry cells,diagnostic panels containing the same and diagnostic methods utilizing the same
US5403573A (en) * 1992-04-23 1995-04-04 The Curators Of The University Of Missouri Radiolabeled protein composition and method for radiation synovectomy
US5541287A (en) 1992-06-09 1996-07-30 Neorx Corporation Pretargeting methods and compounds
US5716596A (en) 1992-06-23 1998-02-10 Diatide, Inc. Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses
US5620675A (en) 1992-06-23 1997-04-15 Diatech, Inc. Radioactive peptides
MD1367C2 (ro) * 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5650134A (en) 1993-01-12 1997-07-22 Novartis Ag (Formerly Sandoz Ltd.) Peptides
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
IL113610A0 (en) * 1994-06-03 1995-08-31 Immunomedics Inc A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same
US5686578A (en) 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US5728369A (en) * 1994-10-05 1998-03-17 Immunomedics, Inc. Radioactive phosphorus labeling of proteins for targeted radiotherapy
US5942210A (en) 1994-11-15 1999-08-24 Cytogen Corporation Methods for lyoprotecting a macromolecule using tricine
US5830431A (en) 1995-06-07 1998-11-03 Mallinckrodt Medical, Inc. Radiolabeled peptide compositions for site-specific targeting
US5961955A (en) * 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
US20020102208A1 (en) * 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90

Also Published As

Publication number Publication date
NO20014245D0 (no) 2001-08-31
HUP0202522A2 (hu) 2002-11-28
CN1345417A (zh) 2002-04-17
MXPA01008837A (es) 2002-05-14
SK288096B6 (sk) 2013-07-02
BRPI0008719A (pt) 2001-12-26
DK1192463T3 (da) 2009-10-05
AU776747B2 (en) 2004-09-23
NO20100717L (no) 2001-10-31
MY138674A (en) 2009-07-31
CA2362119C (en) 2012-12-11
EP2112512A3 (en) 2009-12-16
BG105957A (en) 2002-08-30
BRPI0008719B8 (pt) 2021-07-06
SK12162001A3 (sk) 2002-12-03
HK1045730B (zh) 2006-08-18
JP2002538179A (ja) 2002-11-12
IL145109A0 (en) 2002-06-30
EP2112512B1 (en) 2014-11-19
BRPI0017596B1 (pt) 2015-09-01
HUP1300275A2 (en) 2002-11-28
SI1192463T1 (sl) 2009-10-31
NO20014245L (no) 2001-10-31
ES2526723T3 (es) 2015-01-14
CY1109335T1 (el) 2014-07-02
HRP20010714A2 (en) 2003-02-28
BRPI0017596A2 (pt) 2011-09-27
HRP20010714B1 (hr) 2009-01-31
KR100729247B1 (ko) 2007-06-15
US20020102208A1 (en) 2002-08-01
EP1192463B1 (en) 2009-06-03
HU230516B1 (hu) 2016-10-28
ES2328100T3 (es) 2009-11-10
PL205780B1 (pl) 2010-05-31
DE60042326D1 (de) 2009-07-16
RS51778B (sr) 2011-12-31
RU2251110C2 (ru) 2005-04-27
ZA200106943B (en) 2002-11-22
CA2742153C (en) 2015-04-14
US7608241B2 (en) 2009-10-27
HK1131208A1 (en) 2010-01-15
ATE433108T1 (de) 2009-06-15
KR20020021772A (ko) 2002-03-22
WO2000052473A3 (en) 2002-01-31
EP2112512A2 (en) 2009-10-28
WO2000052473A2 (en) 2000-09-08
BG65690B1 (bg) 2009-06-30
NO329142B1 (no) 2010-08-30
WO2000052473A9 (en) 2001-03-08
TWI294969B (https=) 2008-03-21
UA78484C2 (en) 2007-04-10
SI2112512T1 (sl) 2015-02-27
DK2112512T3 (en) 2014-12-15
NZ513788A (en) 2004-03-26
NO330705B1 (no) 2011-06-20
CZ303262B6 (cs) 2012-07-04
HUP0202522A3 (en) 2011-03-28
CA2742153A1 (en) 2000-09-08
CZ20013126A3 (cs) 2002-07-17
ME00782B (me) 2012-03-20
NZ530868A (en) 2005-12-23
CY1116265T1 (el) 2017-02-08
EE05650B1 (et) 2013-04-15
HU229627B1 (en) 2014-03-28
SK287745B6 (sk) 2011-08-04
US20050169838A1 (en) 2005-08-04
PT2112512E (pt) 2015-01-13
PT1192463E (pt) 2009-09-10
YU61601A (sh) 2004-07-15
PL352531A1 (en) 2003-08-25
BRPI0008719B1 (pt) 2015-07-21
JP4704570B2 (ja) 2011-06-15
EE200100465A (et) 2002-10-15
EP1192463A2 (en) 2002-04-03
HK1045730A1 (en) 2002-12-06
CA2362119A1 (en) 2000-09-08
CZ306959B6 (cs) 2017-10-11
CN1235639C (zh) 2006-01-11
AU3505200A (en) 2000-09-21

Similar Documents

Publication Publication Date Title
BRPI0017596B8 (pt) método para radiomarcação de um anticorpo conjugado a um quelante com 111in para administração a um paciente
BRPI9912227B8 (pt) método para diagnóstico precoce in vitro de carcinomas e de seus estágios iniciais e kit para realização do método.
BRPI0816117B8 (pt) anticorpo monoclonal isolado ou fragmento do mesmo, composiçãofarmacêutica, kit para tratamento de desordens relacionadas com colesterol, e, uso de uma proteína de ligação de antígeno ou de um anticorpo monoclonal ou fragmento do mesmo
ATE153769T1 (de) Prüfungskit
BR0113213A (pt) Método para diagnosticar uma doença auto-imune, anticorpo, composição de diagnóstico, e, uso do anticorpo
Fang et al. Antibody-Directed Cell Internalization of Targeted Covalent Europium Tag Enables In Situ Kinase Labeling and Inductively Coupled Plasma Mass Spectrometry (ICP-MS) Quantification
DK1214447T3 (da) Påvisning af pyruvatkinase-isoenzymer i fæces
ES2186121T3 (es) Mejora de los resultados de los dosificados de inmunodeteccion gracias al empleo de varios trazadores.
KR20020061794A (ko) 류마티스성 자가면역 항체의 검출방법 및 검출키트
ATE277352T1 (de) Einetenascin-c isoform als marker für neoplasmen
ES3042244T3 (en) Fixable viability dyes and their uses
SE9602234D0 (sv) A novel diagnostic method utilizing ECP, and reagents to be used in the methods
ES2060146T3 (es) Metaloproteinasas colagenoliticas asociadas con metastasis.
GR1004636B (el) Προγνωσηατουακαρκινουαμεαχρησηατησαθυμοσινησαβ@α}τβ@bαα

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/09/2015, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/02/00, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2330 DE 01/09/2015 QUANTO AO PRAZO DE VALIDADE. (PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/02/00, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO )

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 29/02/2020